| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 10/30/2001 | CA2052375C Parathyroid hormone derivatives |
| 10/28/2001 | CA2345569A1 Somatostatin antagonists and agonists that act at the sst subtype 2 receptor |
| 10/25/2001 | WO2001079480A1 Albumin fusion proteins |
| 10/25/2001 | WO2001079468A2 Drug metabolizing enzymes |
| 10/25/2001 | WO2001079453A1 Cell culture method, cell cluster obtained by said methods and use thereof |
| 10/25/2001 | WO2001079444A2 Albumin fusion proteins |
| 10/25/2001 | WO2001079443A2 Albumin fusion proteins |
| 10/25/2001 | WO2001079442A2 Albumin fusion proteins |
| 10/25/2001 | WO2001079282A2 Molecules associated with human reproduction |
| 10/25/2001 | WO2001079271A1 Albumin fusion proteins |
| 10/25/2001 | WO2001079258A1 Albumin fusion proteins |
| 10/25/2001 | WO2001079197A1 ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ) |
| 10/25/2001 | WO2001078739A1 Medical combinations comprising tiotropium and fluticasone proprionate |
| 10/25/2001 | WO2001078701A2 Method and compositions for preventing hormone induced adverse effects |
| 10/25/2001 | WO2001078683A2 Sustained release formulations comprising growth hormone |
| 10/25/2001 | WO2001041778B1 Melanin synthesis inhibition compound and composition containing the same |
| 10/25/2001 | WO2001021643A3 Parathyroid hormone analogues for the treatment of osteoporosis |
| 10/25/2001 | WO2001012790A3 Isomerase proteins |
| 10/25/2001 | US20010034364 Isoprenoid pathway inhibitors for stimulating bone growth |
| 10/25/2001 | US20010034044 Genomic sequences for protein production and delivery |
| 10/25/2001 | US20010032643 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
| 10/25/2001 | CA2747325A1 Albumin fusion proteins |
| 10/25/2001 | CA2405709A1 Albumin fusion proteins |
| 10/25/2001 | CA2405701A1 Albumin fusion proteins |
| 10/25/2001 | CA2405563A1 Albumin fusion proteins |
| 10/25/2001 | CA2405557A1 Albumin fusion proteins |
| 10/25/2001 | CA2405550A1 Albumin fusion proteins |
| 10/25/2001 | CA2405525A1 Albumin fusion proteins |
| 10/25/2001 | CA2405451A1 Molecules associated with human reproduction |
| 10/25/2001 | CA2404097A1 Method and compositions for preventing hormone induced adverse effects |
| 10/25/2001 | CA2403644A1 Drug metabolizing enzymes |
| 10/24/2001 | EP1148054A1 Thyroid receptor ligands |
| 10/24/2001 | EP1147223A1 Identifying, monitoring, and treating women for breast precancer or cancer |
| 10/24/2001 | EP1147138A1 Hydrophilic ampholytic polymer |
| 10/24/2001 | EP1147136A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 10/24/2001 | EP1147133A2 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| 10/24/2001 | EP1147124A2 Steroid sulfatase inhibitors and methods for making and using the same |
| 10/24/2001 | EP1147116A1 Boron steroid mimics and pharmaceutical compositions |
| 10/24/2001 | EP1146873A1 Anti-androgens and methods for treating disease |
| 10/24/2001 | EP1146787A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| 10/24/2001 | EP0904064B1 Oral pharmaceutical compositions containing sex hormones |
| 10/24/2001 | CN1319139A Polynucleotide constructs and uses thereof |
| 10/24/2001 | CN1319094A Imidazolyl derivatives |
| 10/23/2001 | US6306914 Progestin therapy for maintaining amenorrhea |
| 10/23/2001 | US6306875 Growth-hormone secretagogues |
| 10/23/2001 | CA2048407C Gonadoliberin antagonists |
| 10/18/2001 | WO2001077681A1 Tpst-assay for diagnosis of autism and related disorders |
| 10/18/2001 | WO2001077327A1 THE HIGH BONE MASS GENE OF 11q13.3 |
| 10/18/2001 | WO2001077177A2 Gpcr-proteins and nucleic acids encoding same |
| 10/18/2001 | WO2001077174A2 Human transporters and ion channels |
| 10/18/2001 | WO2001077139A1 8ss-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS |
| 10/18/2001 | WO2001077138A1 8β-SUBSTITUTED-11β-PENTYL- AND 11β-HEXYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES |
| 10/18/2001 | WO2001077137A1 Albumin fusion proteins |
| 10/18/2001 | WO2001077101A1 Chemical compounds |
| 10/18/2001 | WO2001077093A1 Estrogen agonist/antagonist metabolites |
| 10/18/2001 | WO2001077055A2 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 10/18/2001 | WO2001076619A1 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| 10/18/2001 | WO2001076589A1 Dermatological use and a dermatological preparation |
| 10/18/2001 | WO2001076574A2 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| 10/18/2001 | WO2001076573A2 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
| 10/18/2001 | WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage |
| 10/18/2001 | US20010031786 Antidiabetic agents, obesity |
| 10/18/2001 | US20010031780 Compounds such as (s,s)1-(2-amino-3,3-dimethyl-butyryl)-2,5-dihydro-1h-pyrrole-2 -carbonitrile administered as antidiabetic agents; dipeptidyl peptidase-iv (dpp-iv) |
| 10/18/2001 | US20010031764 3-(4-(2-(5h-dibenzo(a,d)cyclohepten-5-yloxy)-ethoxyl-phenyl)-2 -ethoxy-propionic acid ethyl ester as antidiabetic agents and to treat obesity |
| 10/18/2001 | US20010031762 3-(4-(2-(5h-dibenzo(a,d)cyclohepten-5-yloxy)-ethoxyl-phenyl)-2 -ethoxy-propionic acid ethyl ester as antidiabetic agents and to treat obesity |
| 10/18/2001 | US20010031747 Progestin therapy for maintaining amenorrhea |
| 10/18/2001 | US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders |
| 10/18/2001 | DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma |
| 10/18/2001 | DE10013782A1 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln 4-fluoroalkyl-2H-benzopyrans with antiestrogenic action, processes for their preparation, pharmaceutical compositions containing them and their use for the preparation of medicaments |
| 10/18/2001 | CA2618882A1 Process for preparing stable aqueous surfactant compositions of a crosslinked alkali-swellable acrylate polymer |
| 10/18/2001 | CA2406370A1 Gpcr-proteins and nucleic acids encoding same |
| 10/18/2001 | CA2405912A1 Albumin fusion proteins |
| 10/18/2001 | CA2405895A1 Combination of organic compounds |
| 10/18/2001 | CA2405793A1 Combination of organic compounds |
| 10/18/2001 | CA2405425A1 Dermatological preparations containing thyronine derivatives and uses thereof |
| 10/18/2001 | CA2405070A1 Estrogen agonist/antagonist metabolites |
| 10/18/2001 | CA2404229A1 Human transporters and ion channels |
| 10/18/2001 | CA2403263A1 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 10/18/2001 | CA2403012A1 Chemical compounds |
| 10/18/2001 | CA2402410A1 The high bone mass gene of 11q13.3 |
| 10/17/2001 | EP1145718A1 DICARBA-closo-DODECABORANE DERIVATIVES |
| 10/17/2001 | EP1144997A2 Methods and compounds for modulating nuclear receptor activity |
| 10/17/2001 | EP1144673A1 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith |
| 10/17/2001 | EP1144648A1 Cyclic nucleotide-associated proteins |
| 10/17/2001 | EP1144614A2 33 human secreted proteins |
| 10/17/2001 | EP1144613A1 Methods for making proteins containing free cysteine residues |
| 10/17/2001 | EP1144598A2 Human homologues of proteins regulated by circadian rhythms |
| 10/17/2001 | EP1144595A2 Platform for the differentiation of cells |
| 10/17/2001 | EP1144451A2 Method of modulating cell differentiation or neoplastic trnasformation by altering cadherin-11 expression or function |
| 10/17/2001 | EP1144431A2 16-hydroxyestratrienes as selective estrogens |
| 10/17/2001 | EP1144409A2 Phenyl urea and phenyl thiourea derivatives |
| 10/17/2001 | EP1144396A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 10/17/2001 | EP1144372A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 10/17/2001 | EP1144371A1 Benzenesulphonamide derivatives and their use as mek inhibitors |
| 10/17/2001 | EP1144370A2 Thyroid receptor ligands |
| 10/17/2001 | EP1144369A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 10/17/2001 | EP1144366A2 Use of androgen receptor suppressors |
| 10/17/2001 | EP1144305A1 NOVEL sPLA 2 INHIBITORS |
| 10/17/2001 | EP1144003A1 Methods and devices for delivery of agents to breast milk ducts |
| 10/17/2001 | EP1143988A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases |